GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
Related Articles
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
AACR-KidneyCAN Kidney Cancer Innovation and Discovery Grants
$50,000 over one year for researchers that seek to stimulate creative approaches to translate basic research into new treatment options for kidney cancer.
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies
This cohort study examines if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.
ctDNA Testing Joins NCCN Guidelines for MRD Assessment in DLBCL
The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with…
Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
p53 expression in cytology samples may represent a marker of early‐stage cancer
p53 might be useful in discriminating thyroid follicular lesions. p53 is likely to be a useful diagnostic marker in recognizing indeterminate lesions that are well-differentiated…
Marching through a testicular cancer diagnosis
Grayson Niemi juggled chemo treatments for testicular cancer and practice sessions for joining Ohio State’s marching band. He made the band and also to the…
